Taiwan Advance Bio-Pharmaceutical Bilan de santé
Santé financière contrôle des critères 2/6
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$228.8M and total debt of NT$279.1M, which brings its debt-to-equity ratio to 122%. Its total assets and total liabilities are NT$699.3M and NT$470.5M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$30.2M making its interest coverage ratio 5. It has cash and short-term investments of NT$138.5M.
Informations clés
122.0%
Ratio d'endettement
NT$279.08m
Dette
| Ratio de couverture des intérêts | 5x |
| Argent liquide | NT$138.51m |
| Fonds propres | NT$228.81m |
| Total du passif | NT$470.50m |
| Total des actifs | NT$699.32m |
Mises à jour récentes de la santé financière
Pas de mise à jour
Analyse de la situation financière
Passif à court terme: 4186's short term assets (NT$242.3M) do not cover its short term liabilities (NT$284.7M).
Passif à long terme: 4186's short term assets (NT$242.3M) exceed its long term liabilities (NT$185.8M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 4186's net debt to equity ratio (61.4%) is considered high.
Réduire la dette: 4186's debt to equity ratio has increased from 85.2% to 122% over the past 5 years.
Couverture de la dette: 4186's debt is not well covered by operating cash flow (13.1%).
Couverture des intérêts: 4186's interest payments on its debt are well covered by EBIT (5x coverage).